Chemical Namebelumosudil
Dosage FormTablet (oral; 200 mg)
Drug ClassKinase inhibitors
CompanyKadmon Pharmaceuticals
Approval Year2021


  • For the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy
Last updated on 3/15/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Rezurock (belumosudil) Prescribing Information.2021Kadmon Pharmaceuticals LLC, Warrendale, PA